Navigation Links
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
Date:9/11/2009

ted. They should also talk to their doctor about alcohol consumption. Patients should tell their doctor about all their medicines, including those for migraine, to avoid a potentially life-threatening condition. Symptoms may include high fever, confusion, and stiff muscles. Taking Cymbalta with NSAID pain relievers, aspirin, or blood thinners may increase bleeding risk. Patients should consult with their doctor before stopping Cymbalta or changing the dose. If after starting Cymbalta, patients experience dizziness or fainting upon standing, they should contact their doctor. Cymbalta can increase blood pressure. Healthcare providers should check patients' blood pressure prior to and while taking Cymbalta. Patients should tell their doctor if they experience headache, weakness, confusion, problems concentrating, memory problems, or feel unsteady while taking Cymbalta as this may be signs of low sodium levels. Patients should consult their doctor if they develop problems with urine flow while taking Cymbalta or if they are pregnant or nursing.

The most common side effects of Cymbalta include nausea, dry mouth, sleepiness, and constipation. This is not a complete list of side effects. Cymbalta may cause sleepiness and dizziness. Until patients know how Cymbalta affects them, they should not drive a car or operate hazardous machinery.

For full Patient Information, visit http://www.cymbalta.com.

For full Prescribing Information, including Boxed Warning and medication guide, visit http://www.cymbalta.com.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Yoga Benefits Back-Pain Patients
2. Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) EXPRESS(R) Stents and Bypass Surgery
3. CRESTOR(R) Reduced Risk of Cardiovascular Events in Elderly Patients in New Analysis of Jupiter
4. New Large-Scale, Global Study Provides Additional Information About an Intensified Dose-Regimen of PLAVIX(R) in Acute Coronary Syndrome Patients Undergoing Angioplasty
5. Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
6. Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study
7. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. ANA773 Demonstrates Significant Antiviral Response in Early Clinical Trial in Hepatitis C Patients
10. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
11. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... SAN FRANCISCO , June 2, 2015  Nektar ... Texas MD Anderson Cancer Center today announced a research ... evaluate NKTR-214, a CD122-biased cytokine designed to preferentially stimulate ... cells found naturally in the body.  CD122, which is ... a key signaling receptor that is known to increase ...
(Date:6/2/2015)... , June 2, 2015 Northstar ... first television and multi-media commercial advertisement, which it ... to promote SNORenz®, the company,s top selling product. ... the company,s past success with television advertising. Previous ... but this, more modern version takes an entertainment-oriented ...
(Date:6/2/2015)... und MADRID , ... Mündliche Präsentation (Abstract   10503), vorgestellt ... Clinical Oncology    PharmaMar teilt ... ( Janssen) Daten der multizentrischen Phase-3-Studie ... Verbesserung beim progressionsfreien Überleben (progression-free survival, PFS) ...
Breaking Medicine Technology:Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 2Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 3Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 4Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 5Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine 6Northstar releases its direct response multi-media ad designed to be used in national television advertising campaigns 2PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 2PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 3PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 4PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 5PharmaMar gibt bekannt, Janssens Studie zeige, dass Trabectedin die Krankheitsbekämpfung bei Patienten mit fortgeschrittenem Weichgewebesarkom verbessert 6
... Ltd. (NYSE Amex: CPD ) announced that ... (Sun) have been extended until January 28, 2012 but ... which was originally set to expire in January 2010, ... and is being extended for an additional 1 year ...
... Pharmaceutical Company (NYSE: KVa/KVb) today announced the filing of its ... with the Securities and Exchange Commission.  As a result, the ... 2010 Form 10-K to enable its securities to continue trading ... is currently working on preparing and filing its quarterly reports ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 2Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 2K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 3K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 4K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 5K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 6K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 7K-V Pharmaceutical Company Announces Filing of Fiscal Year 2010 Annual Report on Form 10-K With the Securities and Exchange Commission 8
(Date:6/2/2015)... a popular online store selling celebrity inspired fashion products, ... dresses. The company carries more than 1000 styles of ... a wide variety of summer events like wedding and ... quality trendy special occasion dresses and accessories. ... and cotton. Their products feature a wide range of ...
(Date:6/2/2015)... June 02, 2015 First Choice ... emergency rooms in the United States, named Kenneth Alan ... – Jones Road facility. , “We are pleased ... Houston-Jones Road facility,” said Dr. James M. Muzzarelli, Executive ... Dr. Totz received his undergraduate degree from St. Edwards ...
(Date:6/2/2015)... 2015 Thermi, formerly ThermiAesthetics, a ... successfully transitioned into its new company headquarters in ... company’s continued rapid worldwide expansion and houses the ... 25 Thermi employees, including those of the warehousing, ... “As one of the fastest growing aesthetic companies ...
(Date:6/2/2015)... MA (PRWEB) June 02, 2015 Join us ... Anniversary Awareness Walk in Honor of Rhonda Martin , who ... members have since dedicated their resources to raising awareness and ... seeks to raise awareness in hopes that there will be ... , All are welcome and encouraged to join the ...
(Date:6/1/2015)... 2015 The National Association of ... as a 2015-2016 inductee into its VIP Woman of ... distinction for leadership in business. NAPW is the nation’s ... than 700,000 members and over 200 operating Local Chapters. ... honor,” said NAPW President Star Jones. “Job satisfaction is ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Kenneth Alan Totz as New Medical Director of Houston – Jones Road Facility 2Health News:Thermi Moves to New Corporate Headquarters as Rapid Company Expansion Continues 2Health News:New Awareness Raising Event in Westwood, NJ to Benefit Renowned Brain Aneurysm Foundation 2Health News:National Association of Professional Women Inducts Miriam Wirski, Holistic Life Coach, Into its VIP Woman of the Year Circle 2
... Results of two new studies suggest that low-dose estrogen ... experiencing menopausal hot flushes and bleeding. The June issue ... as effective as high-dose estrogen in treating menopausal symptoms. ... irregular bleeding.// , ...
... brain imaging techniques, scientists have indicated the patterns in ... to be stored or deleted. The study was done ... (MIT) and reported to the American Association for the ... ,The researchers coupled a number of different brain parts ...
... Australian researchers have identified a gene which allows the ... drugs.Plasmodium,is a single-celled organism which is transmitted to ... historically evaded control efforts by building resistance to virtually ... is hoped that the new discovery will lead to ...
... treat nausea, and research at the University of Sydney ... studies have shown that the active ingredients in ginger ... ingredient of chilli peppers and capsicum, a known pain ... the body called the vanilloid receptor, which sits on ...
... the hair loss associated with drug treatment for cancer. ,This ... a frequent side effect of cancer therapy and is often ... lives.// ,Currently, there is no effective way to stop ... attempt to minimise hair loss is to fit patients with ...
... researchers at Peterson Medical College, a strategy was developed ... Immunodeficiency Virus (HIV) out of dormancy in the cellular ... Samoan rainforest tree, and appears to stimulate the virus, ... body's immune system to detect and attack it.// ...
Cached Medicine News:Health News:An effective pain killer, 2Health News:Breakthrough in cancer therapy 2Health News:Prostratin- Drug to eradicate HIV 2
Biocryl™ Acrylic Foldable Lens....
The STAAR ELASTIMIDE lens, combines the best of foldable lens technology with traditional design. This lens contains a cast-molded, silicone optic with modified Polyimide haptics....
... The Bausch & Lomb UV-Absorbing, Silicone Posterior ... for primary implantation for the visual correction ... age or older in whom the cataractous ... extraction methods. This device is intended to ...
... lenses are manufactured using the ... Perspex CQ UV PMMA material ... and single piece lenses. Unioptic ... both nonphaco and phaco styles. ...
Medicine Products: